Investors / United States / Pathway to Cures
Pathway to Cures
Investor · New York, NY, United States · North America
Pathway to Cures is the National Bleeding Disorders Foundation's venture philanthropy fund, created to accelerate development of cures and therapies for inheritable blood and bleeding disorders. It makes equity investments in therapies and technologies, reinvesting proceeds back into the fund, and partners with venture capital, biotech and pharma companies to close the early-stage funding gap.
Invests inHealthcare & BiotechMedia & Entertainment
In its own wordsblood disordersrare diseasetherapeuticsdiagnosticsventure philanthropybiotech
Your fit with Pathway to Cures
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsPathway to Cures lists 4 checked portfolio companies on its own site and is named in 1 funding round, 1 of them as lead. Its largest themes are Healthcare & Biotech (75%) and Media & Entertainment (25%). 33% of its companies are based in Ireland. It invests most often alongside Capital Factory, Creative Destruction Lab and Netra Health.
Counts come from funding rounds that name Pathway to Cures, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Entry stage
share of companies by the stage of its first roundPathway to Cures does not state its stages on its site, so only what it does is shown.
The rounds that name Pathway to Cures do not give a stage.
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 1 | 1 |
| '26 | 0 | 0 |
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 75% | 15% |
| Media & Entertainment | 25% | 4% |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Capital Factory | 1 |
| Creative Destruction Lab | 1 |
| Netra Health | 1 |
| Wave Ventures | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers4100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Co-investor network
who it backs companies with, and who they back togetherCompare Pathway to Cures head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Pathway to Cures| Date | Company | Stage |
|---|---|---|
| 20 Nov 2025 | Round Led |
Round details for Pathway to Cures
Amounts, full round histories and every co-investor in Pathway to Cures' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
4 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Afimmune is a drug discovery and development company focused on the development of bioactive lipids for the treatment of rare and inflammatory diseases. | Healthcare & Biotech | Portfolio page | ||
| Anvesana is leveraging RNAseq analysis platform to treat rare genetic disorders caused by gene dosage effects. | Media & Entertainment | Portfolio page | ||
| SeraGene Therapeutics is a pre-clinical stage biotech company reimagining the treatment of coagulation disorders through innovative RNA and nanomedicine technologies. | Healthcare & Biotech | Nov 2025Round | Page + round | |
| Spark Biomedical develops and provides transcutaneous auricular neurostimulation treatments for opioid withdrawal relief and addiction disorders | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- pathwaytocures.org
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 20 Nov 2025
- Companies checked
- 4
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Pathway to Cures' profile as data
Pull Pathway to Cures' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/pathwaytocures.org
# also
GET /v1/firms/pathwaytocures.org/portfolio
GET /v1/firms/pathwaytocures.org/coinvestors
GET /v1/firms/pathwaytocures.org/news